You are currently viewing a new version of our website. To view the old version click .
Vaccines
  • Correction
  • Open Access

11 December 2023

Correction: Rockman et al. Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines 2023, 11, 52

,
,
,
,
,
and
1
CSL Seqirus Ltd., Parkville, VIC 3050, Australia
2
Department of Immunology and Microbiology, The University of Melbourne, Parkville, VIC 3050, Australia
3
CSL Seqirus Ltd., Maidenhead SL6, UK
4
CSL Seqirus Ltd., Summit, NJ 07901, USA
The authors would like to make the following corrections to this published paper [1]. An incorrect color was assigned to season effectiveness in Figure 1d and Figure 2, due to a line color error that occurred transferring the figure from a graphics program to a word processing format. The color of the last column in Figure 1d and the color of the last column in Figure 2 (top) were both corrected. The corrected figures are shown below:
Figure 1. Seasonal influenza vaccine effectiveness in the US as estimated by the Centers for Disease Control and Prevention (CDC) [15–25]. (a) Proportions of identified virus types, subtypes, and lineages by year. (b) Adjusted vaccine effectiveness for influenza A strains. (c) Adjusted vaccine effectiveness for influenza B strains. (d) Adjusted overall seasonal effectiveness. Error bars for (bd) indicate adjusted 95% confidence interval. ND, no data.
Figure 2. CDC-adjusted overall vaccine effectiveness estimates and documented A/H3N2 antigenic match or mismatch each season, as shown in Figure 1 (top), with numbers of US hospitalizations (middle) and deaths (bottom) due to influenza [15–24,26–29].
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

  1. Rockman, S.; Laurie, K.; Ong, C.; Rajaram, S.; McGovern, I.; Tran, V.; Youhanna, J. Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness. Vaccines 2023, 11, 52. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.